Your browser does not support iframes.
300 million people globally suffer from asthma, a chronic disease of the lungs characterized by recurrent attacks of breathlessness and wheezing.
In the US alone, 30 million people suffer from asthma which accounts for more than 10 million missed school days, and more than 14 million missed work days annually. The economic and societal burden of asthma is immense. Asthma can also be life-threatening, accounting for a quarter of a million deaths annually worldwide.According to the WHO, 64 million people have chronic obstructive pulmonary disease (COPD), a lung ailment characterized by a persistent blockage of airflow from the lungs. More than 3 million people die of COPD each year and the WHO expects COPD to become the world’s third-leading cause of death by 2030.
Teva is focused on developing and providing treatment options that address two major issues within the current treatment landscape for respiratory diseases: 1) treatment adherence and compliance and 2) treating asthma that remains uncontrolled despite the use of a standard of care therapy.In the treatment of asthma, the goal is to maintain asthma control so people with asthma can maintain good lung function, exhibit fewer symptoms and experience fewer asthma attacks. Teva delivers a range of respiratory medicines today, including controller and rescue therapy. We are also committed to the development of new treatment options. Teva’s focus is on combining our integrated strengths in specialty medicines (including both small molecules and biologics), device platforms and generics. In addition to our currently available medicines, Teva has a broad pipeline of treatment options currently in development with the goal of further enhancing our product offerings and addressing unmet needs within the respiratory community.
Patients often experience difficulties with the use of their inhalers and incorrect inhaler use can be linked to asthma exacerbations and ineffective control of asthma and COPD. Improper inhaler use can result in acute attacks of asthma or COPD and may increase the utilization of emergency care.Teva has developed a new, breath-actuated, dry-powder inhaler (DPI) device platform to deliver both maintenance and rescue therapies. This dry-powder delivery system is designed to be easier to use than traditional metered-dose inhaler (MDIs). DPIs deliver a dose of medication through breath actuation simply by inhaling. These devices further eliminate the need to coordinate activation of the device with taking a breath – a barrier to effective administration of inhaled medications from traditional MDIs.